Louis Maes Selected Research

Therapeutics

4/2023	To Target or Not to Target Schistosoma mansoni Cyclic Nucleotide Phosphodiesterase 4A?
12/2021	6-Methyl-7-deazapurine nucleoside analogues as broad-spectrum antikinetoplastid agents.
12/2021	7-Aryl-7-deazapurine 3'-deoxyribonucleoside derivative as a novel lead for Chagas' disease therapy: in vitro and in vivo pharmacology.
11/2021	DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis.
2/2020	Phenotypic adaptations of Leishmania donovani to recurrent miltefosine exposure and impact on sand fly infection.
1/2019	Optimization and Characterization of a Galleria mellonella Larval Infection Model for Virulence Studies and the Evaluation of Therapeutics Against Streptococcus pneumoniae.
1/2018	Miltefosine-resistant Leishmania infantum strains with an impaired MT/ROS3 transporter complex retain amphotericin B susceptibility.
1/2018	Discovery of benzimidazole-based Leishmania mexicana cysteine protease CPB2.8ΔCTE inhibitors as potential therapeutics for leishmaniasis.
1/2017	Optimization and characterization of a murine lung infection model for the evaluation of novel therapeutics against Burkholderia cenocepacia.
8/2012	Evaluation of the anti-adhesive effect of milk fat globule membrane glycoproteins on Helicobacter pylori in the human NCI-N87 cell line and C57BL/6 mouse model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Louis Maes Research Topics

Disease

27	Infections 03/2022 - 01/2004
20	Visceral Leishmaniasis (Kala Azar) 12/2023 - 01/2009
10	Leishmaniasis 12/2021 - 09/2003
10	African Trypanosomiasis (Nagana) 01/2020 - 02/2010
9	Chagas Disease (American Trypanosomiasis) 01/2023 - 01/2009
7	Neglected Diseases 11/2021 - 03/2016
7	Malaria 02/2021 - 08/2010
4	Neoplasms (Cancer) 01/2017 - 06/2010
3	Trypanosomiasis 01/2022 - 10/2018
3	Parasitic Diseases (Parasitic Disease) 11/2020 - 10/2010
3	Cutaneous Leishmaniasis 10/2020 - 02/2011
2	Parasitemia 03/2022 - 01/2021
2	Inflammation (Inflammations) 10/2020 - 01/2017
2	Dry Eye Syndromes (Dry Eye Syndrome) 10/2020 - 01/2016
2	Candidiasis (Moniliasis) 10/2020 - 07/2020
2	Respiratory Syncytial Virus Infections 01/2019 - 01/2017
2	Necrosis 11/2018 - 04/2013
2	Tuberculosis (Tuberculoses) 01/2017 - 03/2016
2	Dermatitis 06/2014 - 11/2010
2	Body Weight (Weight, Body) 02/2011 - 06/2004
2	HIV Infections (HIV Infection) 09/2008 - 02/2004
1	Schistosomiasis (Bilharziasis) 04/2023
1	Giardiasis 01/2022
1	Communicable Diseases (Infectious Diseases) 01/2021
1	Brain Neoplasms (Brain Tumor) 11/2020
1	Vulvovaginal Candidiasis 07/2020
1	Virus Diseases (Viral Diseases) 01/2020

Drug/Important Bio-Agent (IBA)

12	miltefosine (Impavido)IBA 01/2021 - 11/2012
7	N(1)-methyl-2-lysergic acid diethylamide (MIL)IBA 01/2021 - 02/2013
5	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2020 - 10/2012
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 04/2011
4	Antimalarials (Antimalarial Agents)IBA 02/2021 - 04/2010
3	OxazinesIBA 02/2021 - 01/2017
3	VaccinesIBA 01/2021 - 01/2018
3	LipidsIBA 10/2020 - 11/2018
3	diethylstilbestrol monophosphate (PDES)IBA 01/2020 - 10/2018
3	liposomal amphotericin B FDA Link 01/2018 - 06/2004
3	pretomanidIBA 01/2018 - 03/2016
3	Cysteine Proteases (Cysteine Protease)IBA 01/2018 - 10/2010
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2017 - 06/2011
3	oleylphosphocholineIBA 01/2016 - 11/2012
3	Antimony Sodium Gluconate (Sodium, Stibogluconate)IBA 02/2011 - 01/2004
3	SaponinsIBA 03/2009 - 09/2003
2	benzonidazole (benznidazole)IBA 01/2021 - 01/2019
2	Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA 10/2020 - 01/2017
2	Serine Proteases (Serine Protease)IBA 10/2020 - 05/2013
2	Sialic Acid Binding Ig-like Lectin 1IBA 01/2020 - 01/2017
2	Cyclic AMP (AMP, Cyclic)IBA 01/2020 - 01/2020
2	Neutralizing AntibodiesIBA 01/2019 - 01/2018
2	Virulence Factors (Pathogenicity Factors)IBA 01/2019 - 04/2014
2	Polysaccharides (Glycans)IBA 01/2019 - 01/2019
2	EnzymesIBA 10/2018 - 04/2013
2	Peptide Hydrolases (Proteases)FDA Link 01/2017 - 01/2011
2	Paromomycin (Paromomycin Sulfate)FDA LinkGeneric 01/2015 - 01/2012
2	PX-6518IBA 02/2011 - 01/2004
2	Plant ExtractsIBA 09/2010 - 06/2010
2	maesabalide IIIIBA 01/2005 - 06/2004
2	TriterpenesIBA 06/2004 - 09/2003
1	Electron Transport Complex III (Coenzyme Q-Cytochrome-c Reductase)IBA 12/2023
1	2-aminobenzimidazoleIBA 01/2023
1	Purine NucleosidesIBA 03/2022
1	pyridazineIBA 01/2022
1	NucleosidesIBA 01/2022
1	PurinesIBA 12/2021
1	Primaquine FDA Link 02/2021
1	Antiparasitic Agents (Antiparasitics)IBA 02/2021
1	CarbamatesIBA 02/2021
1	Investigational DrugsIBA 02/2021
1	pyrimidineIBA 01/2021
1	Red Fluorescent ProteinIBA 01/2021
1	imidazopyridineIBA 01/2021
1	Anti-Infective Agents (Microbicides)IBA 01/2021
1	pyridineIBA 01/2021
1	fluorescent protein 583IBA 01/2021
1	Firefly LuciferasesIBA 01/2021
1	MetalsIBA 11/2020
1	selenolIBA 11/2020
1	LigandsIBA 11/2020
1	dithiolIBA 11/2020
1	Auranofin (Ridaura)FDA Link 11/2020
1	SeleniumIBA 11/2020
1	Thioredoxin-Disulfide ReductaseIBA 11/2020
1	GoldIBA 11/2020
1	trypsin-like serine proteaseIBA 10/2020
1	TrypsinIBA 10/2020
1	Amphotericin B (Amphotericin)FDA LinkGeneric 07/2020
1	Indicators and Reagents (Reagents)IBA 01/2020
1	PyrazolonesIBA 01/2020
1	Interferon-alpha (Interferon Alfa)IBA 01/2020
1	Interferon Type IIBA 01/2020
1	pyrazoloneIBA 01/2020
1	purineIBA 01/2020
1	Oxygen (Dioxygen)IBA 01/2019
1	Capsules (Microcapsules)IBA 01/2019
1	Peptides (Polypeptides)IBA 01/2019
1	Free RadicalsIBA 01/2019
1	imidazoleIBA 01/2019

Therapy/Procedure

11	Therapeutics 04/2023 - 02/2004
4	Drug Therapy (Chemotherapy) 01/2018 - 09/2008
1	Oral Administration 03/2022